Real-World Data on Second-Line Therapy with Ramucirumab for Metastatic Gastric Cancer: A Two-Center Study on Romanian Population
Diana Galos, Loredana Balacescu, Radu Vidra, Daniel Sur · 2023
Read Real-World Data on Second-Line Therapy with Ramucirumab for Metastatic Gastric Cancer: A Two-Center Study on Romanian Population by Diana Galos, Loredana Balacescu, Radu Vidra, Daniel Sur (2023) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-10744814.txt.
Description
Galos, Balacescu, Vidra, and Sur report real world results for a second line drug in spread stomach cancer in twenty twenty-three. The drug, ramucirumab, blocks vessel growth that feeds tumors. It can be given alone or with a second drug. The team reviewed sixty-nine patients treated at two centers in Romania between twenty eighteen and twenty twenty-two.
Half the group lived a year and a half after starting the drug. Time without the cancer growing ran just under five months. Blood side effects were most common when the drug was paired. Tiredness and headache led the list for the drug alone. More treatment rounds went with longer survival. The results match the known safety picture from trials.
Catalog record
| CREATOR | Diana Galos, Loredana Balacescu, Radu Vidra, Daniel Sur |
|---|---|
| YEAR | 2023 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 30 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |